State and Pharma: a Meaningful Dialogue
The issues of local production in Russia of vaccines, blood products, insulins and drugs for treatment of HIV were discussed at the round table of the Russian Union of Industrialists and Entrepreneurs , organized by the RUIE, Chamber of Industry and Commerce of the Russian Federation, Union of Associations and Industries of Pharmaceutical and Medical Industry. It was the first meeting of industry representatives after Vladimir Putin signed the list of instructions on additional measures to develop pharmaceutical industry in the Russian Federation.
The meeting was held by RUIE President Alexander Shokhin, Executive Vice-President of RUIE, Chairman of Health Industry Commission Victor Cherepov. The round table gathered Deputy Minister of Industry and Trade of the Russian Federation Sergey Tsyb and Director of Pharmaceutical Industry Development Department. Representatives of pharmaceutical companies – manufacturers of insulins, vaccines, blood products and HIV drugs and a representative of patient organization of haemophilia patients took part in the discussion.
The main report of the RUIE Commission Chairman on Pharmaceutical and Medical Industry Yuri Kalinin, was devoted to problems of the Russian market of insulins, vaccines, blood products and HIV drugs and the role of local manufacture in its development. A comprehensive analysis of current situation with these groups of products was made.
Deputy minister of industry and trade of the Russian Federation Sergey Tsyb, while recognizing the importance of meaningful dialogue between the state and pharma, quoted figures pointing to accomplishments in that area. He acknowledged the role of complex measures of state support and activity of investors, with over 10 modern pharmaceutical enterprises constructed within the last three years. Sergey Tsyb remarked that the Ministry of Industry and Trade pays special attention to centralized state purchase on certain groups of expensive socially important drugs, increased “transparency” of public purchase. Besides, development of nuclear medicine, support of scientific research and production of innovative products for the “next generation” will be the priority areas.
The ministry plans to develop criteria of “localization depth” and accordingly – making preferences to the manufacturers.